Authors
Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nora Schweitzer, Arndt Vogel, Michael P Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, Joerg F Schlaak, Arndt Weinmann, Marcus A Wörns, Peter Galle, Winnie Yeo, Frankie Mo, Stephen L Chan, Helen Reeves, Trevor Cox, Philip Johnson
Publication date
2016/6/1
Journal
Clinical Gastroenterology and Hepatology
Volume
14
Issue
6
Pages
875-886. e6
Publisher
WB Saunders
Description
Background & Aims
GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance.
Methods
We collected data on cancer diagnosis and outcomes of 6834 patients (2430 with HCC and 4404 with chronic liver disease) recruited from Germany, Japan, and Hong Kong. We also collected data from 229 patients with other hepatobiliary tract cancers (cholangiocarcinoma or pancreatic adenocarcinoma) and 92 healthy individuals (controls). For reference, the original UK cohort (on which the GALAD model initially was …
Scholar articles
S Berhane, H Toyoda, T Tada, T Kumada… - Clinical Gastroenterology and Hepatology, 2016